U.S. markets closed

Koninklijke Philips N.V. (RYLPF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
60.61+0.02 (+0.03%)
At close: 1:37PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close60.60
Open60.52
Bid0.00 x 0
Ask0.00 x 0
Day's Range59.76 - 60.61
52 Week Range53.74 - 61.06
Volume738
Avg. Volume8,240
Market Cap54.545B
Beta (5Y Monthly)0.68
PE Ratio (TTM)38.78
EPS (TTM)1.56
Earnings DateN/A
Forward Dividend & Yield1.02 (1.68%)
Ex-Dividend DateMay 10, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Philips Joins Forces with National Minority Quality Forum to Address Healthcare Disparities
    Business Wire

    Philips Joins Forces with National Minority Quality Forum to Address Healthcare Disparities

    Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it is working with the National Minority Quality Forum (NMQF), as part of a joint mission to ensure that high-risk racial and ethnic populations and communities receive increased access to quality healthcare. NMQF uses evidence-based, data-driven initiatives to guide programs and deliver educational and advocacy programs, a national health index, research and community-based programs. In collaboration with Philips, NMQF will work to raise awareness and support of key issues such as maternal mortality among Black women, leveraging Philips resources and technology to help close the healthcare disparities gaps.

  • Five-year patient-level meta-analysis of ILLUMENATE EU RCT and Pivotal study results confirms safety profile of Philips Stellarex .035” low-dose Drug-Coated Balloon
    GlobeNewswire

    Five-year patient-level meta-analysis of ILLUMENATE EU RCT and Pivotal study results confirms safety profile of Philips Stellarex .035” low-dose Drug-Coated Balloon

    Philips Stellarex low-dose drug-coated balloon April 20, 2021 Stellarex is the only Drug-Coated Balloon (DCB) to consistently demonstrate no difference in mortality every year through five years when compared with percutaneous transluminal angioplasty (PTA), the current standard of care Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the five-year patient-level meta-analysis of two major randomized controlled trials (RCTs). The findings, which represent the highest level of the evidence pyramid [1], confirm the long-term safety of the Philips Stellarex Drug-Coated Balloon (DCB). The meta-analysis shows no difference in mortality at each year through five years for patients treated with the Stellarex low-dose DCB when compared with those treated with percutaneous transluminal angioplasty (PTA), the current standard of care. The meta-analysis was presented at the 2021 Charing Cross International Symposium. The ILLUMENATE EU RCT and ILLUMENATE Pivotal RCT meta-analysis comprises approximately 600 patients in Europe and the U.S., and is the largest homogenous patient data set of paclitaxel DCB RCTs with five-year follow-up [2,3]. After five years, the meta-analysis for the two studies shows no difference in survival rates, with 80.4% for the Stellarex DCB arm and 80.4% for the PTA arm. The analysis also demonstrates that the use of one or multiple Stellarex DCBs in a patient is not a predictor of mortality. The meta-analysis has a vital status follow-up compliance of over 90%. “This meta-analysis confirms and reinforces the consistent and durable long-term safety profile of the low-dose Stellarex DCB through five years,” said William Gray, MD, FACC, FSCAI, and President of the Lankenau Heart Institute, an investigator for the Stellarex clinical trials who presented the results. “The results are an important contribution to the long-term safety of paclitaxel-coated devices.” “Stellarex is the only paclitaxel DCB to consistently demonstrate no difference in mortality every year through five years compared to PTA in multiple RCTs and in a patient-level meta-analysis,” said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. “We are committed to providing healthcare providers with accurate and transparent data to help them make an informed decision on the optimal treatment for each patient with peripheral arterial disease. With its low drug dose and unique drug coating composition, Stellarex is a logical choice for those who require this option.” Featuring Philips EnduraCoat technology, a unique coating consisting of a polyethylene glycol excipient with amorphous and crystalline paclitaxel particles dispersed in it, Philips Drug-Coated Balloon – Stellarex .035” is unlike any other DCB for the treatment of peripheral artery disease. EnduraCoat technology provides efficient drug transfer and effective drug residency coupled with high coating durability and minimal particulate loss, thereby enabling a low therapeutic drug dose. Philips’ Image Guided Therapy business provides complete procedural solutions of systems, smart devices, disease-specific software and services for minimally invasive procedures, helping caregivers decide, guide, treat and confirm the right therapy for each patient during their procedure. [1] https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence. [2] Katsanos et al. Risk of Death Following Application of Paclitaxel‐Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. JAHA, December 8, 2018.[3] Schneider et al. Paclitaxel exposure: Long-term safety and effectiveness of a drug-coated balloon for claudication in pooled randomized trials. Catheterization & Cardiovascular Interventions, August 24, 2020. For further information, please contact: Mark GrovesPhilips Global Press OfficeTel.: +31 631 639 916E-mail: mark.groves@philips.com Fabienne van der FeerPhilips Image Guided TherapyTel: + 31 622 698 001E-mail: fabienne.van.der.feer@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. Attachment Philips Stellarex low-dose drug-coated balloon

  • Philips produces one hundred millionth blade for its OneBlade, the product that disrupted the grooming market
    GlobeNewswire

    Philips produces one hundred millionth blade for its OneBlade, the product that disrupted the grooming market

    Blades for OneBlade in package Blades for OneBlade in production in factory Blades for OneBlade in production April 20, 2021 Since its launch in 2016, the Philips OneBlade has disrupted grooming markets worldwide, creating a new category - a single tool for shaving, trimming and edgingOneBlade Face + Body adds the ability to trim, style and edge facial and body hair even in the most intimate areasOne hundred million blades is an important milestone - Philips’ global innovation teams will keep expanding the OneBlade range and engaging new audiences Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the production of its one hundred millionth OneBlade blade. This impressive milestone is testament to the success of the collaborative effort put in by Philips’ grooming innovation team in the Netherlands, who teamed up with other Philips innovation teams around the globe to produce the advanced OneBlade shaving and grooming tool, sharing their expertise and experience. The team keeps on innovating and disrupting the grooming market with new OneBlade solutions, such as the OneBlade Face + Body, and will keep on pushing the boundaries by expanding the ranges and engaging new audiences. The Philips OneBlade subscription-model makes the grooming routine as easy and convenient as possible; new blades get delivered to people’s doorstep. “At Philips, we believe people should be able to embrace their individuality so they can be what they want to be, not just today but next year and the year after,” said Dominique Oh, Business Leader Grooming and Beauty at Philips. “It’s why our innovation teams continue to develop tools that allow them to achieve the look they want in an easy way or find the look that’s right for them. I am proud to see this unique blade, designed and invented by Philips for OneBlade, reaching the important milestone of 100 million blades produced.” The must-have styling tool of a new generationOver the last few years, there has been a major shift in facial hair styles that has completely disrupted the grooming market. People worldwide, especially millennials (18 - 34 year olds), are shaving less, styling more, and expressing their individualism by styling their facial hair. Despite this widespread change in behavior, which had not previously been seen for decades, the tools at their disposal had hardly changed until Philips disrupted the shaving and grooming market in 2016 with a new solution - the OneBlade. This unique single tool allows users to style, trim and edge any length of facial hair in complete comfort and convenience. The OneBlade already boasts over 27 million users worldwide, with the number still growing fast. Continued innovation in premium grooming and beautyIn addition to working on OneBlade innovations, Philips brings other innovations to the personal care market, such as the premium, highly advanced and successful Philips Lumea IPL 9000 series hair removal device for home use, and its new series 9000 electric shavers with SkinIQ technology for those who are looking for a close shave while maintaining healthy looking skin. Today, Philips keeps reinventing the premium space, delivering smart propositions that provide personalized plans and guidance, and stepping into new business models. For further information, please contactLaura SeikrittPhilips Global Press OfficeTel: +31 6 20740318E-mail: Laura.Seikritt@philips.com Marije AnsingPhilips Global Press OfficeTel: +31 6 50589016E-mail: Marije.Ansing@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. Attachments Blades for OneBlade in package Blades for OneBlade in production in factory Blades for OneBlade in production